96. Jahrestagung der Deutschen Gesellschaft für Pathologie e. V ...

More documents

Recommendations

Info

FR-P-037 MALDI imaging reveals COX7A2, TAGLN2 and S100-A10 as novel prognostic markers in Barrett’s Cancer M . Elsner 1 , S . Rauser 1 , S . Maier 1 , C . Schöne 1 , B . Balluff 1 , S . Meding 1 , G . Jung 1 , M . Nipp 1 , H . Sarioglu 1 , G . Maccarone 2 , U . Jütting 1 , A . Feuchtinger 1 , R . Langer 3 , M . Feith 3 , B . Küster 4 , M . Ueffing 1 , H . Zitzelsberger 1 , H . Höfler 3 , A . Walch 1 1 Helmholtz-Zentrum München, Neuherberg, 2 Max Planck Institute of Psychiatry, München, 3 Technische Universität München, Neuherberg, 4 Technische Universität München, Chair of Proteomics and Bioanalytics, München Aims. In order to characterize proteomic changes found in Barrett’s cancer and its premalignant stages, the proteomic profiles of histologically proposed precursor and invasive carcinoma lesions were analyzed by MALDI imaging mass spectrometry (MALDI imaging). Methods. For a primary proteomic screening, a discovery cohort of 38 fresh frozen Barrett’s Cancer samples was used, with the goal to find intestinal metaplasia and Barrett’s cancer specific proteins that might be used as markers for cancer development as well as for lymph node metastasis and disease outcome. Based on this cohort we studied 33 areas of Barrett’s Cancer and 11 areas of intestinal metaplasia. Protein identification was done by mass spectrometry. To validate the identified proteins, immunohistochemistry was performed on an independent validation set of 102 Barrett’s Cancer cases and the results were correlated to clinical data. Results. We detected 60 m/z species that are significantly differentially expressed in intestinal metaplasia and invasive carcinoma (p50 IEL/HPF) and mild (
Abstracts FR-P-040 MicroRNA expression profiling for prediction of resistance to neoadjuvant radiochemotherapy in squamous cell carcinoma of the oesophagus J . Slotta-Huspenina 1 , E . Drecoll 1 , M . Feith 2 , C . Wagner 3 , H . Höfler 1 , 4 , K . Becker 1 , R . Langer 1 1 Technical University of Munich, Institute of Pathology, München, 2 Technical University of Munich, Department of Surgery, 3 IMGM Laboratories GmbH, Martiensried, 4 Institute of Pathology, Helmholtz-Zentrum München, Oberschleissheim Aims. MicroRNA (miRNA) expression has been shown to play an important role in biology of malignant tumours, including sensitivity to chemotherapy and radiation. Neoadjuvant radiochemotherapy (RCTX) followed by surgery is a standard treatment strategy for locally advanced oesophageal squamous cell carcinoma (ESCC). However, a subset of patients does not respond to RCTX. In the present study we evaluated whether miRNA profiles can predict resistance to RCTX in ESCC. Methods. 31 patients with locally advanced ESCC (cT3-4, cN1-3, M0-1) underwent preoperative radiochemotherapy with cisplatin, 5-fluorouracil and 30-45 Gy, followed by resection of the oesophagus. Tumour response was evaluated by histopathological tumour regression. MiRNA profiling was done in pre-therapeutic formalin-fixed and paraffin embedded (FFPE) biopsies using the Agilent Human Microarray platform (Release 16.0), encompassing 1205 human miRNAs. Differential expression was identified in responders (n=15) and non-responders (n=16) by applying appropriate biostatistics to the data and validated by real-time quantitative PCR (qRT-PCR). Results. Even if the miRNA expression profiles of pre-therapeutic ESCC biopsies within and between non-responders (n=16) and responders (n=15) were highly similar (average correlation coefficients r=0.96, 0.94 and 0.95), ten differentially expressed miRNAs could be identified by microarray analysis in non-responders and responders of ESCC (p
Page 2 and 3:
Inhalt Der Pathologe · Supplement
Page 4 and 5:
Inhalt Der Pathologe · Supplement
Page 6 and 7:
Editorial Liebe Kolleginnen und Kol
Page 8 and 9:
Kolorektales Karzinom 2 VO-005 Tran
Page 10 and 11:
Keynote Lecture VO-014 Genetic dete
Page 12 and 13:
(AMACR, FASN, GOLM1, GSP-pi, ERG) t
Page 14 and 15:
to assess the correct rate of R1 re
Page 16 and 17:
DNA damage, and cytotoxic drugs. Au
Page 18 and 19:
HCV-positive formalin-fixed and par
Page 20 and 21:
well as MET activation were examine
Page 22 and 23:
or BRAF mutation, c-MYC and SIRT1 e
Page 24 and 25:
AG Pneumopathologie III DO-032 Remo
Page 26 and 27:
immature granulopoiesis showed a st
Page 28 and 29:
ned, if well-defined mantle zones,
Page 30 and 31:
phomas). Most prominent gains or am
Page 32 and 33:
DO-062 Tumor-associated macrophages
Page 34 and 35:
DO-080 DOG1: an immunohistochemical
Page 36 and 37:
AG Oralpathologie DO-087 Detection
Page 38 and 39:
DO-094 Do activated fibroblasts inf
Page 40 and 41:
DO-101 Histopathological analysis o
Page 42 and 43:
DO-108 Identification of potential
Page 44 and 45:
Conclusions. In conclusion, 454 par
Page 46 and 47: subgroup of patients with B-Raf mut
Page 48 and 49: DO-002b Impact of terminologies in
Page 50 and 51: Methods. We performed MCPyV-FISH of
Page 52 and 53: FR-013 HPV-genotype distribution in
Page 54 and 55: Methods. Three different techniques
Page 56 and 57: (i.e. investment in equipment and e
Page 58 and 59: FR-032 COLD-PCR: a powerful tool in
Page 60 and 61: dissection (MBLND) technique to imp
Page 62 and 63: SO-005 Prevalence of mutations in s
Page 64 and 65: SO-011 Methylation profiling and in
Page 66 and 67: more effective than SAHA alone and
Page 68 and 69: SO-022 Specialized pathology review
Page 70 and 71: SO-027 Ki-67 in mitotic score group
Page 72 and 73: nificantly associated with advanced
Page 74 and 75: liver did not correlate with the mu
Page 76 and 77: AG Paidopathologie II SO-046 Overex
Page 78 and 79: Results. Histomorphology of the ova
Page 80 and 81: p42 and p27 have not yet been inves
Page 82 and 83: SO-068 Recent advances in understan
Page 84 and 85: SO-075 A novel, dual role of CCN3 i
Page 86 and 87: Pancreatic Adenocarcinoma SG-137 Se
Page 88 and 89: sease and 30 colon cancer serum sam
Page 90 and 91: Conclusions. Although CRC is charac
Page 92 and 93: differentiated and TNM stage III or
Page 94 and 95: pressed moderate levels of the prot
Page 98 and 99: in the context of therapy response
Page 100 and 101: on primary cells of wild-type and c
Page 102 and 103: chemotherapy was recommended and co
Page 104 and 105: aims are twofold: 1) to verify the
Page 106 and 107: Results. Her2/neu status in TMAs an
Page 108 and 109: prognostic impact was found in rect
Page 110 and 111: provided information on survival ti
Page 112 and 113: Methods. Biopsy specimens from 430
Page 114 and 115: the OS rate was 53% for patients wi
Page 116 and 117: FR-P-098 Immunohistological stainin
Page 118 and 119: FR-P-104 Histopathological evaluati
Page 120 and 121: within the earliest morphologic det
Page 122 and 123: Conclusions. In primary imaging a g
Page 124 and 125: fibrotic neointma development as we
Page 126 and 127: FR-P-129 Alpha-1-antitrypsin-PiZ-an
Page 128 and 129: FR-P-136 The expression of central
Page 130 and 131: cosa and in the periarterial tissue
Page 132 and 133: FR-P-149 Combination of Castleman d
Page 134 and 135: or without different concentrations
Page 136 and 137: Results. In 18 cases (79%) the caus
Page 138 and 139: FR-P-168 Autopsy findings in a 2-ye
Page 140 and 141: FR-P-174 MPGN-like glomerulonephrit
Page 142 and 143: Poster: Gynäkopathologie und Mamma
Page 144 and 145: SA-P-011 Genetic aberrations of pre
Page 146 and 147:
Mechanismen, die eine Progression d
Page 148 and 149:
internet server. A network of inter
Page 150 and 151:
Methods. HE-gefärbte Schnittpräpa
Page 152 and 153:
Conclusions. The newly released 450
Page 154 and 155:
and desmoplastic reaction are diffe
Page 156 and 157:
one patient revealed more than 9 mi
Page 158 and 159:
situation, the V600E mutation in th
Page 160 and 161:
SA-P-064 Evolution of molecular pat
Page 162 and 163:
nic markers such as myf4 and MyoD1
Page 164 and 165:
Conclusions. To our knowledge, this
Page 166 and 167:
SA-P-085 Expression of the eukaryot
Page 168 and 169:
Results. The papillary RCC type II
Page 170 and 171:
SA-P-098 Male infertility: assessme
Page 172 and 173:
SA-P-104 Process oriented scientifi
Page 174 and 175:
Conclusions. The IBDW offers a uniq
Page 176 and 177:
L Lasitschka F. DO-046 Lehmann A. F
show all

96. Jahrestagung der Deutschen Gesellschaft für Pathologie e. V ...

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?